Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer.
作者信息
Christopoulos Petros
机构信息
Department of Medical Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.
Translational Lung Research Center at Heidelberg University Hospital, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
出版信息
Transl Lung Cancer Res. 2023 Jul 31;12(7):1364-1368. doi: 10.21037/tlcr-23-347. Epub 2023 Jul 25.
Abstract
摘要
相似文献
1
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer.应对驱动基因阴性非小细胞肺癌脑转移的挑战。
Transl Lung Cancer Res. 2023 Jul 31;12(7):1364-1368. doi: 10.21037/tlcr-23-347. Epub 2023 Jul 25.
2
Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer.免疫疗法与放射疗法联合治疗非小细胞肺癌脑转移
J Thorac Dis. 2021 May;13(5):3315-3322. doi: 10.21037/jtd-2019-rbmlc-08.
3
[Research Progress of Immunotherapy for Brain Metastases in Patients
with Drive Gene Negative NSCLC].[驱动基因阴性非小细胞肺癌患者脑转移免疫治疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):610-614. doi: 10.3779/j.issn.1009-3419.2018.08.06.
4
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.免疫检查点抑制剂治疗脑转移瘤：神经外科医生入门。
Neurosurgery. 2020 Sep 1;87(3):E281-E288. doi: 10.1093/neuros/nyaa095.
5
Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.程序性细胞死亡 1 通路抑制剂可改善有脑转移的小细胞肺癌患者的总生存期。
J Cancer Res Clin Oncol. 2023 May;149(5):1825-1833. doi: 10.1007/s00432-022-04121-y. Epub 2022 Jun 23.
6
Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.PD-1/PD-L1 抑制剂在非小细胞肺癌伴脑转移患者中的疗效：中国真实世界回顾性研究。
Thorac Cancer. 2021 Nov;12(22):3019-3031. doi: 10.1111/1759-7714.14171. Epub 2021 Oct 1.
7
Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study.免疫疗法联合全脑放疗治疗驱动基因阴性的非小细胞肺癌脑转移瘤：一项回顾性研究
Future Oncol. 2024 Apr 9:1-14. doi: 10.2217/fon-2023-1061.
8
Systemic Therapy for Lung Cancer Brain Metastases.肺癌脑转移的全身治疗
Curr Treat Options Oncol. 2021 Oct 25;22(12):110. doi: 10.1007/s11864-021-00911-7.
9
Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.日本真实世界研究：初诊非小细胞肺癌脑转移患者的管理与结局。
Oncology. 2020;98(7):460-467. doi: 10.1159/000506368. Epub 2020 Mar 27.
10
Outcomes of Gamma Knife Radiosurgery for Brain Metastases From Anaplastic Lymphoma Kinase Rearrangement-Positive and EGFR Mutation-Positive Non-Small Cell Lung Cancer.伽玛刀放射外科治疗间变性淋巴瘤激酶重排阳性和表皮生长因子受体突变阳性非小细胞肺癌脑转移瘤的疗效
Cureus. 2021 Dec 13;13(12):e20398. doi: 10.7759/cureus.20398. eCollection 2021 Dec.
本文引用的文献
1
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).阿特珠单抗联合卡铂和培美曲塞治疗未经治疗的脑转移的晚期非鳞状非小细胞肺癌患者的 II 期临床试验（Atezo-Brain，GECP17/05）。
J Clin Oncol. 2023 Oct 1;41(28):4478-4485. doi: 10.1200/JCO.22.02561. Epub 2023 Aug 21.
2
Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.不同疗法对非小细胞肺癌脑转移的疗效：一项系统评价和荟萃分析。
Transl Lung Cancer Res. 2023 Apr 28;12(4):689-706. doi: 10.21037/tlcr-22-515. Epub 2023 Mar 20.
3
How I treat brain metastases of melanoma.我是如何治疗黑色素瘤脑转移的。
ESMO Open. 2022 Dec;7(6):100598. doi: 10.1016/j.esmoop.2022.100598. Epub 2022 Oct 20.
4
Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.肺癌脑转移患者的分级预后评估（GPA）：小细胞肺癌 GPA 的初步报告和非小细胞肺癌 GPA 的更新，包括程序性死亡配体 1 及其他预后因素的影响。
Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):60-74. doi: 10.1016/j.ijrobp.2022.03.020. Epub 2022 Mar 21.
5
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.布加替尼与克唑替尼用于初治的晚期ALK阳性非小细胞肺癌：3期ALTA-1L试验的最终结果
J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16.
6
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.帕博利珠单抗联合铂类化疗治疗 NSCLC 合并稳定脑转移患者的疗效：KEYNOTE-021、-189 和 -407 的汇总分析。
J Thorac Oncol. 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12.
7
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.解析 ALK 和 EGFR 阳性肺腺癌中的免疫抑制性肿瘤微环境。
Cancer Immunol Immunother. 2022 Feb;71(2):251-265. doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14.
8
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.在致癌基因驱动的肺癌中，局部治疗的时机、技术和分子特征对大脑控制的影响。
ESMO Open. 2021 Jun;6(3):100161. doi: 10.1016/j.esmoop.2021.100161. Epub 2021 Jun 2.
9
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.癌症多特异性抗体的原理和当前临床现状。
Int J Mol Sci. 2021 May 26;22(11):5632. doi: 10.3390/ijms22115632.
10
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.洛拉替尼用于经治的ALK或ROS1阳性肺癌及TP53共突变的影响：德国早期准入项目的结果
Ther Adv Med Oncol. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021.
Zotero 插件